Brokerages expect Savara Inc (NASDAQ:SVRA) to report earnings per share (EPS) of ($0.39) for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for Savara’s earnings, with the lowest EPS estimate coming in at ($0.46) and the highest estimate coming in at ($0.33). Savara reported earnings of ($0.32) per share in the same quarter last year, which would indicate a negative year over year growth rate of 21.9%. The company is expected to issue its next quarterly earnings report on Wednesday, May 8th.
According to Zacks, analysts expect that Savara will report full year earnings of ($1.55) per share for the current fiscal year, with EPS estimates ranging from ($1.93) to ($1.26). For the next year, analysts forecast that the business will report earnings of ($1.40) per share, with EPS estimates ranging from ($1.86) to ($0.97). Zacks’ EPS averages are an average based on a survey of sell-side analysts that follow Savara.
Savara (NASDAQ:SVRA) last posted its quarterly earnings results on Wednesday, March 13th. The company reported ($0.29) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.37) by $0.08.
In related news, CFO David L. Lowrance sold 7,500 shares of Savara stock in a transaction on Monday, April 8th. The stock was sold at an average price of $9.02, for a total value of $67,650.00. Following the completion of the sale, the chief financial officer now owns 2,446 shares of the company’s stock, valued at $22,062.92. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Jaakko Taneli Jouhikainen sold 25,000 shares of Savara stock in a transaction on Monday, April 8th. The stock was sold at an average price of $9.03, for a total value of $225,750.00. Following the completion of the sale, the insider now directly owns 184,754 shares of the company’s stock, valued at approximately $1,668,328.62. The disclosure for this sale can be found here. Insiders sold 42,761 shares of company stock valued at $385,749 in the last ninety days. 6.10% of the stock is currently owned by corporate insiders.
Several institutional investors and hedge funds have recently modified their holdings of SVRA. FMR LLC bought a new stake in shares of Savara in the fourth quarter worth $2,830,000. Vanguard Group Inc grew its holdings in shares of Savara by 23.6% in the third quarter. Vanguard Group Inc now owns 1,246,240 shares of the company’s stock worth $13,908,000 after acquiring an additional 238,358 shares during the period. Vanguard Group Inc. grew its holdings in shares of Savara by 23.6% in the third quarter. Vanguard Group Inc. now owns 1,246,240 shares of the company’s stock worth $13,908,000 after acquiring an additional 238,358 shares during the period. BlackRock Inc. grew its holdings in shares of Savara by 8.2% in the third quarter. BlackRock Inc. now owns 2,170,294 shares of the company’s stock worth $24,220,000 after acquiring an additional 164,056 shares during the period. Finally, Morgan Stanley grew its holdings in shares of Savara by 224.1% in the third quarter. Morgan Stanley now owns 205,560 shares of the company’s stock worth $2,294,000 after acquiring an additional 142,140 shares during the period. 48.42% of the stock is owned by institutional investors.
Shares of SVRA stock traded up $0.31 during mid-day trading on Friday, hitting $9.32. The company’s stock had a trading volume of 95,906 shares, compared to its average volume of 184,692. Savara has a 52-week low of $6.21 and a 52-week high of $14.06. The company has a debt-to-equity ratio of 0.23, a current ratio of 15.63 and a quick ratio of 15.63. The stock has a market capitalization of $333.94 million, a P/E ratio of -7.22 and a beta of 0.86.
Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.
Featured Article: Different Types of Derivatives
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Savara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Savara and related companies with MarketBeat.com's FREE daily email newsletter.